Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. - Wikidata - awgldk - TriplyDB

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.

http://www.wikidata.org/entity/Q34378331

about

Alzheimer mechanisms and therapeutic strategies GSPE interferes with tau aggregation in vivo: implication for treating tauopathy Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease NMR Meets Tau: Insights into Its Function and Pathology Molecular Mechanisms in the Pathogenesis of Alzheimer's disease and Tauopathies-Prion-Like Seeded Aggregation and Phosphorylation Diverse molecular targets for therapeutic strategies in Alzheimer's disease Dye-binding assays for evaluation of the effects of small molecule inhibitors on amyloid (aβ) self-assembly The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies Secondary Metabolites in Ramalina terebrata Detected by UHPLC/ESI/MS/MS and Identification of Parietin as Tau Protein Inhibitor Methylene Blue (Tetramethylthionine Chloride) Influences the Mobility of Adult Neural Stem Cells: A Potentially Novel Therapeutic Mechanism of a Therapeutic Approach in the Treatment of Alzheimer's Disease.Structural determinants of Tau aggregation inhibitor potency Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden.Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau.Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation.In silico theoretical molecular modeling for Alzheimer's disease: the nicotine-curcumin paradigm in neuroprotection and neurotherapy.Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors.Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.cis-Glyco-fused benzopyran compounds as new amyloid-β peptide ligands.Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.Effects of Various Flavonoids on the α-Synuclein Fibrillation Process.Structure of core domain of fibril-forming PHF/Tau fragments.Cellular and molecular actions of Methylene Blue in the nervous system Methylene blue modulates β-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease.Naturally occurring multipotent anti-Alzheimer's agents.Resveratrol inhibits the formation of multiple-layered β-sheet oligomers of the human islet amyloid polypeptide segment 22-27 Structure and mechanism of action of tau aggregation inhibitors.Simultaneous quantification of methylene blue and its major metabolite, azure B, in plasma by LC-MS/MS and its application for a pharmacokinetic study.PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction in vivo.Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease.

P2860

Q22252311-A4B7BEED-DE73-4266-9B0E-24F9F7DC5538 Q24628862-3D0FFC19-9893-4563-B2AA-0A806FF72C62 Q24657235-B6D5C19D-36A6-413B-B898-E71FC96E39C8 Q26739412-2FC5245B-0FE0-4D0A-99E6-867CCCAE3020 Q26747418-B4305503-2741-417A-AE83-FD3E78D9A9B0 Q26748105-415CA356-3511-4123-B6C7-A02E9968723F Q26827193-659E8DF5-1A37-46B9-BC32-1FA3F26192EF Q26852205-9F2E5458-D159-4B8D-8CA8-0CFCFA597E22 Q28119005-69D20A28-1147-4E40-9032-743FFEE32EE1 Q28259424-E1C213C1-8E97-4EDD-90A4-2AD9FD3DB588 Q28484481-DAF11406-FEF9-4DCA-8EB7-B11F21AF3CCA Q28597211-78ADA30C-1AD1-4297-8867-496E486F5263 Q28828799-1B85065D-3415-41DD-A6DB-158508555B36 Q30313363-ACD1D470-DCFA-4541-B5D9-B4B228317173 Q30353954-2E4AEC7C-DD1C-4DF2-8E15-298CCA845940 Q30481896-C18AC644-FE87-4E09-9748-901416FCA1EB Q30497435-CA519E30-F268-432A-BE92-565BEB9E1B0A Q30649677-3D72F5A1-44A2-4D3E-907E-CA8E6FD71B56 Q31047131-F2ECCD22-92AD-48F3-8703-BE885408E772 Q33283794-2B026A4D-EB2D-469A-941E-588E6A2159B6 Q33826249-EBA55D92-84BE-4AA2-B675-BD85C446290C Q33828966-FC38EB92-CA7B-4142-90F3-F5083E9999FA Q33861802-0F3E4D26-8799-4CCA-A9BA-79F3DF1F38A0 Q34000176-4A94F220-295D-4016-981A-DED68B85A233 Q34003885-2C9932F6-6387-4485-BF62-FE4FA0144CFB Q34066654-A335AC50-C12C-4AAF-A1AE-5EF359E98CE2 Q34068459-601E3CE9-8F85-4F86-8656-0741325D713C Q34154643-5FDEC3BC-EF65-4DB7-BB79-4197EA9B0C58 Q34185176-C0AD9410-8AB5-4BA0-9740-58C72E663F50 Q34211735-981C92FE-2EDD-4A57-9EA1-1A696923D3C7 Q34354306-3C13F4FC-D6E2-402B-BDE6-D036BAE47061 Q34422385-00452C84-24F6-45F6-8C8C-13A5FCF25C12 Q34430920-24BA56E3-7FAB-4194-B5CA-10AF6CF75EFB Q34610487-47F467F1-7ECB-4F92-BBCD-C4ACC30C7326 Q34621248-AA7FF255-B94D-48FA-94F9-E32A8B17BD7F Q34688893-CF03B41E-95C1-431F-9B36-6362BFA3D4B6 Q34902096-92BA87A6-C09E-4FAA-9BFD-DFD3620AF928 Q35016575-D2B6A477-B896-47FE-BE0A-704B9AB2C25D Q35058484-22B235B4-FCC1-4B42-8642-A424D6E1A003 Q35064974-010D758F-B4FC-4C9D-A096-AC463200778B

P2860

Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.

http://www.wikidata.org/entity/Q34378331

description

2004 nî lūn-bûn

@nan

2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@ast

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@en

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@nl

type

label

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@ast

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@en

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@nl

prefLabel

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@ast

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@en

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@nl

P1433

Q34378331-1FA75E23-C446-4466-BB48-93A9BFE0B3DD

P1476

Q34378331-86932EFA-30A7-4842-B4A7-92ED616C4C52

P2093

Q34378331-1D765E14-4FD6-428D-8850-0AD5288CB576

Q34378331-70360F39-7B59-4E11-AD50-704503DDA9CC

Q34378331-742FADE0-E748-4CEC-813E-105CA4F1637B

Q34378331-844C129B-4100-4215-A173-AC79A63A8CD4

Q34378331-9AD4907A-7FD4-4D72-A5A5-2293B907B64A

Q34378331-CE4830D0-F4E8-4971-ADB7-8FD394CAA8C5

Q34378331-FE073016-8E02-44F3-8953-9651266570C6

P2860

Q34378331-00441C67-23E2-4A6D-92A1-B7EA36529D6E

Q34378331-04259FD0-07B0-4D73-B47E-8D7C8B0D6DF8

Q34378331-06AA9C1C-06B0-4234-AACB-E8DAF5EC865E

Q34378331-10A74B38-F083-4E84-A993-929400117AC4

Q34378331-12FD11C0-438E-499C-AE87-5E2A19BB1CBD

Q34378331-18970FEA-B787-4548-8442-CC3F2F6AD5A1

Q34378331-1E2C68A4-77FE-420D-A047-FA05D6430916

Q34378331-2B2A04FF-93A6-4D7F-8E46-5C9B7D8351E8

Q34378331-2D289DC8-653A-4867-A447-5576D1DE6079

Q34378331-3BCD279F-860B-4F85-864A-17267350BBD3

P304

Q34378331-9F5FAC16-689A-4EE2-A0CB-F35937F0A77A

P31

Q34378331-BD7A8CC5-FDA6-4D01-B6F1-E1FF3EF96D62

P356

Q34378331-9BBCB235-BF40-4283-81D6-0FF162220353

P407

Q34378331-A06FBA19-4905-4A8E-B48B-6D74AA95318D

P433

Q34378331-9CF58A4C-B793-49DB-9C32-C327B095D4B8

P478

Q34378331-A71C54CB-BAC2-4F94-91C2-B7DF835534C1

P577

Q34378331-6B675364-90BD-4911-92F6-93BCE2E45A82

P698

Q34378331-59B3FB70-FAFC-498D-BDD2-34879950222E

P921

Q34378331-514C46D4-ECF8-49EB-A84A-C641408619F2

P356

P1433

Journal of Biological Chemistry

P1476

Inhibition of heparin-induced ...... , polyphenols, and porphyrins.

@en

P2093

Masami Masuda

http://www.w3.org/2001/XMLSchema#string

Masato Hasegawa

http://www.w3.org/2001/XMLSchema#string

Michel Goedert

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Suzuki

http://www.w3.org/2001/XMLSchema#string

Sayuri Taniguchi

http://www.w3.org/2001/XMLSchema#string

Shin-ichi Hisanaga

http://www.w3.org/2001/XMLSchema#string

Takeshi Iwatsubo

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease

Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

Shattuck lecture--neurodegenerative diseases and prions

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17

Candidate gene for the chromosome 1 familial Alzheimer's disease locus

Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease

Neurodegenerative tauopathies

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

P304

7614-7623

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M408714200

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

280

http://www.w3.org/2001/XMLSchema#string

P577

2004-12-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15611092

http://www.w3.org/2001/XMLSchema#string

P921